• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar

McCarter & English Logo

  • People
  • Services
  • Insights
  • Our Firm
    • Leadership Team
    • Social Justice
    • Diversity & Inclusion
    • Pro Bono
    • Client Service Values
  • Join Us
    • Lawyers
    • Summer Associates
    • Patent Professionals
    • Professional Staff
    • Job Openings
  • Locations
    • Boston
    • Philadelphia
    • East Brunswick
    • Stamford
    • Hartford
    • Trenton
    • Newark
    • Washington, DC
    • New York
    • Wilmington
  • Share

Share

Browse Alphabetically:

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
  • All
Bankruptcy, Restructuring & Litigation
Blockchain, Smart Contracts & Digital Currencies
Business Litigation
Cannabis
Coronavirus Resource Center
Corporate
Crisis Management
Cybersecurity & Data Privacy
Delaware Corporate, LLC & Partnership Law
Design, Fashion & Luxury
E-Discovery & Records Management
Energy & Utilities
Environment & Energy
Financial Institutions
Government Affairs
Government Contracts & Global Trade
Government Investigations & White Collar Defense
Healthcare
Immigration
Impact Investing
Insurance Recovery, Litigation & Counseling
Intellectual Property
Labor & Employment Law
Life Sciences
Manufacturing
Products Liability, Mass Torts & Consumer Class Actions
Proptech
Public Finance 
Real Estate
Renewable Energy
Sports & Entertainment
Tax & Employee Benefits 
Technology Transactions
Transportation, Logistics & Supply Chain Management
Trusts, Estates & Private Clients 
Venture Capital & Emerging Growth Companies
  • Broadcasts
  • Events
  • News
  • Publications
  • View All Insights
Search By:
Media item displaying COVID-19 Spotlights Ruling’s Chilling Effect on Diagnostic Tests
Main image for COVID-19 Spotlights Ruling’s Chilling Effect on Diagnostic Tests
News|Quote

COVID-19 Spotlights Ruling’s Chilling Effect on Diagnostic Tests

Bloomberg Law

3.23.2020

The new coronavirus outbreak highlights how a 2012 U.S. Supreme Court decision has discouraged drugmakers from developing new diagnostic tests for diseases like Covid-19—a problem that should be addressed, intellectual property lawyers said.

Mayo “disincentivized a lot of diagnostic companies from developing these tests in general,” Maria Zacharakis, a member of McCarter & English’s IP practice and managing partner of the Boston office, said.

“These tests are very expensive to develop and patent protection is necessary,” Zacharakis said. “The same costs are associated with developing Covid-19 tests, and the same disincentivization will be there. Though there may be more incentive because of the pandemic and the government involvement.”

More information

sidebar

pdfemail

Related People

Media item: Maria Laccotripe Zacharakis, PhD
Maria Laccotripe Zacharakis, PhD

Partner

Related Services

Coronavirus Resource Center
Intellectual Property
Subscribe to our Insights
McCarter & English, LLP
Copyright © 2021 McCarter & English, LLP. All Rights Reserved.
  • Login
  • Attorney Advertising
  • Privacy
  • Awards Methodology
  • Contact
  • Subscribe
  • Sitemap

The McCarter & English, LLP website is for informational purposes only. We do not provide legal advice on this website. We can provide legal advice only to our clients in specific inquiries that they address to us. If you are interested in becoming a client, please contact us, but do not send any information about your specific legal question. We cannot serve as your lawyers until we establish an attorney-client relationship, which can occur only after we follow procedures within our firm and after we agree to the terms of the representation.

Accept Cancel